Last reviewed · How we verify
doxecitine and doxribtimine
At a glance
| Generic name | doxecitine and doxribtimine |
|---|---|
| Also known as | MT1621, GMP grade dC/dT (deoxycytidine and deoxythymidine) |
| Sponsor | UCB BIOSCIENCES, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Diarrhea
- Alanine aminotransferase increased (ALT)
- Vomiting
- Abdominal pain (including abdominal pain upper)
- Aspartate aminotransferase increased (AST)
Serious adverse events
- Diarrhea requiring hospitalization
- Diarrhea requiring permanent discontinuation
- Elevated liver enzymes requiring permanent discontinuation
Key clinical trials
- An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency (PHASE2)
- Doxecitine and Doxribtimine-Expanded Access
- Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- doxecitine and doxribtimine CI brief — competitive landscape report
- doxecitine and doxribtimine updates RSS · CI watch RSS
- UCB BIOSCIENCES, Inc. portfolio CI